You just read:

Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Feb 14, 2019, 08:00 ET